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Aim:Previous studies suggest that circulating levels of interleukin-18 (IL-18)maybeprospectively related
to risk of coronary heart disease (CHD) in the general population. We report new data from the largest
prospective study to date, which are combined with data from all published prospective studies in a
meta-analysis.
Methods: We measured baseline IL-18 levels in stored serum samples of subjects from a case–control
study nested within a prospective study of 5661 men aged 40–59 years recruited from general practices
in 18 British towns in 1978–1980 and followed-up for up to 16 years (median time to event 8.4 years)
for fatal CHD and non-fatal myocardial infarction (595 cases, 1238 controls).
Results: IL-18 concentrations were strongly related to cigarette smoking, triglyceride, HDL-cholesterol
(inversely) and to circulating levels of several inﬂammatory and haemostatic markers. Men in the top
third of baseline IL-18 levels had an age-adjusted odds ratio (OR) for CHD of 1.55 (95% CI 1.21, 1.98)
compared with those in the lowest third; this was reduced to 1.30 (95% CI 0.99, 1.69) after additional
adjustment for vascular risk factors and 1.12 (95% CI 0.84, 1.49) after further adjustment for CRP and IL-6.
In meta-analyses of CVD, associations (or effect sizes) were consistent between studies; RRs were 1.63
(95% CI 1.46, 1.82) after age adjustment, 1.39 (95% CI 1.24, 1.55) after additional risk factor adjustment
and 1.34 (95% CI 1.17, 1.54) after additional adjustment for inﬂammatory markers.
Conclusions: Circulating IL-18 is prospectively and independently associated with CVD risk.Atherosclerosis includes an important inﬂammatory compo-
ent [1]; a substantial body of evidence demonstrates prospective
ssociations between circulating acute-phase reactant proteins
particularly C-reactive protein [CRP] and ﬁbrinogen) and coronary
eart disease (CHD) risk [2,3]. More recently, growing evidence
uggests that levels of circulating pro-inﬂammatory cytokines, par-
icularly interleukin-6 (IL-6), are prospectively related to CHD risk
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[4]. However, evidence about the inﬂuence of circulating levels of
other pro-inﬂammatory cytokines is more limited.
Interleukin-18 (IL-18) is a pleiotropic proinﬂammatory cytokine
which plays an important role in the inﬂammatory cascade [5].
Some evidence suggests that its expression may be related to
atherosclerotic plaque progression and vulnerability [6,7]. Circu-
lating concentrations of IL-18 have been prospectively related to
vascular events in patients with stable and unstable angina [8] or
pre-existing CHD [9,10] and, more recently in nested case–control
studies carried out within a population-based studies of healthy
adults [11–14]. In order to clarify the strength and independence
of this relationship further, we report here on the relationship
between IL-18 and CHD risk in a large prospective study with
considerably more events than in previous studies: a nested
case–control study of middle-aged British men, nested within a
large prospective study (the British Regional Heart Study), inwhich
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e have previously reported data on the relations of CRP and IL-6
o CHD [4,15]. To place our results in context, we have performed
systematic review and meta-analysis of all published prospective
tudiesexamining the relationshipof IL-18andCHD,alsocorrecting
or regression dilution bias.
. Methods
.1. British Regional Heart Study
In 1978–1980, 7735 men aged 40–59 years were randomly
elected from general practice registers in each of 24 British
owns and invited to take part in the British Regional Heart Study
response rate 78%). Nurses administered questionnaires, made
hysical measurements, recorded an electrocardiogram (ECG) and
ollected non-fasting venous blood samples; in 5661 men in 18
f the study towns, serum was stored at −20 ◦C for subsequent
nalysis [16]. Pre-existing CHD was deﬁned on the basis of a his-
ory of a doctor diagnosis of CHD, a positive history of angina
r possible MI on the Rose (WHO) chest pain questionnaire or
n ECG consistent with deﬁnite or possible CHD. All men were
onitored subsequently for all-cause mortality and for cardiovas-
ular morbidity, with a follow up loss of <1% [17]. Fatal CHD cases
ere ascertained through National Health Service Central Regis-
ers on the basis of a death certiﬁcate with ICD-9 codes 410-414.
he diagnosis of non-fatal myocardial infarction (MI) was based
n reports from general practitioners, supplemented by regular
eviews of general practice records, and diagnosed in accordance
ithWorldHealthOrganisation criteria [17]. Anested case–control
tudywas established, based on all 643 CHD cases (279 CHDdeaths
nd 364 cases of non-fatal MI) occurring between 1978 and 1995
nd a total of 1278 controls (2 per case) “frequency matched” to
ases on town of residence and age in 5-year bands was randomly
elected from amongmenwho had survived to the end of the study
eriod (31/12/1995) free from incident CHD (themaximum follow-
p time was 16 years and among the cases, the median time to
vent was 8.4 years). Serum samples were available for 595 of
hese cases and 1238 controls for IL-18 measurements to be car-
ied out in 2004–2005. A sub-sample of 158 men had fasting serum
amples drawn in both 1996 and 2000, and these were analysed
or IL-18, in 2004–2005 in the same laboratory using the same
ethods [4], in order to correct associations for regression dilution
ias.
.2. Laboratory methods
Serum concentrations of IL-18 and IL-6 were assayed using
nzyme immunoassays (R and D Systems, Oxford, UK) by labo-
atory personnel who were blind to the case–control status of
amples. The intra- and inter-assay coefﬁcients of variation for IL-
8 were 5.6% and 10.4% respectively. CRP, serum amyloid A (SAA),
ntercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion
olecule 1 (VCAM-1), E-selectin, P-selectin, von Willebrand fac-
or (vWF), ﬁbrin-D dimer and tissue plasminogen activator (t-PA)
ntigen were assayed as previously reported [15,18–21].
.3. Statistical analysis
We pre-speciﬁed case–control analyses by thirds of IL-18 val-
es in controls. Unmatched stratiﬁed logistic regression was ﬁtted
sing unconditional maximum likelihood methods (SAS version
.1). Models were ﬁtted adjusted for (i) age (model 1), (ii) addi-
ionally for cigarette smoking (model 2), (iii) additionally for
ther established cardiovascular risk factors (blood pressure, total
holesterol, HDL cholesterol, body mass index [as continuous
ovariates], history of diabetes, history of CHD, social class androsis 217 (2011) 227–233
usual physical activity [as categorical covariates]) (model 3) and (iv)
additionally for other inﬂammatory markers (IL-6 and C-reactive
protein [continuous covariates, log transformed because of skewed
distribution]) (model 4). Rosner’s method for univariate models
wasused tocalculate regressiondilution ratios (RDRs)onasubsetof
men with repeated IL-18 measurements, using a linear regression
model of the repeat measurement predicted by the ﬁrst measure-
ment [22].
1.4. Systematic review
A systematic review of all papers, letters, abstracts and review
articles reporting on prospective associations between circulat-
ing interleukin-18 levels and CHD risk was conducted according
to PRISMA guidelines. Relevant studies published between 1945
(Webof Science), 1970 (PubMed), 1974 (Embase) andOctober 2009
were identiﬁed from databases, by scanning reference lists and
review articles and consulting experts in the ﬁeld. Additionally,
studieswere sought using a combined textword andMESH/subject
heading (for PubMed and Embase only) using the search strat-
egy detailed in Web Table 1. The review was restricted to studies
carried out on human subjects and written in the English lan-
guage. Studies eligible for inclusion in the current review included
prospective cohort studies or nested case–control studies based
on approximately general populations (where participants were
not selected on the basis of pre-existing disease) and prospec-
tive studies of patients with pre-existing coronary artery disease
(CAD). Populations deﬁned using other criteria (for example, pre-
existing diabetes or metabolic syndrome) were excluded. Studies
had to include at least one year of follow-up for CHD events follow-
ing baseline IL-18 measurements. Relevant CHD events included
fatal CHD, non-fatal CHD or all CHD (fatal and non-fatal). Studies
including CHD and stroke outcome in a combined “cardiovascu-
lar disease” end point were included, although a sub-analysis was
conducted to check for differences in the associations between
IL-18 and CHD and CVD endpoints. Data were extracted by two
researchers in accordance with a pre-speciﬁed ﬁxed protocol;
discrepancies were resolved by discussion. Odds ratios (ORs) or
hazard ratios (HRs) providing estimates of relative risk (RR) for
CHD for the highest third of the control IL-18 distribution com-
pared with the lowest third were sought, in models adjusted for:
(i) age (and gender where appropriate) (model 1), (ii) age and
established cardiovascular risk factors (particularly blood lipids,
cigarette smoking, blood pressure, diabetes) (model 2) and (iii)
age, established cardiovascular risk factors and other inﬂammatory
markers (IL-6 and C-reactive protein) (model 3). If estimates could
not be obtained from published reports, they were sought directly
from study authors, with supplementary descriptive data as
required.
1.5. Statistical analysis
The meta-analysis was carried out using STATA 10. Estimates
of log ORs or log HRs for different studies were combined using
an inverse-variance weighted average in a ﬁxed effects model:
ﬁxed effects were chosen over random effects because we did
not have reason to expect different magnitude of results between
studies. Between-study heterogeneity was assessed using the I2
statistic. Funnel plots were examined and tests described by Begg
[23] and Egger [24] for small study bias were also performed.
Pre-speciﬁed sensitivity analyses were undertaken using metare-
gression to investigate heterogeneity between studies with (i)
CVD endpoints (combined CHD and other cardiovascular end-
points) compared to CHD and (ii) studies of approximately
general populations compared with studies of patients with
CAD.
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Table 1
Baseline characteristics of men with coronary heart disease and of age and town-matched controls. Mean (SD) or n (%).
Cases Controls p (no difference)
(n=595) (n=1238)
Age (years) 52.6 (5.2) 52.5 (5.3) Matched
Current smoker (n, %) 304 (51.2) 521 (42.2) <0.001
Evidence of coronary disease (n, %) 247 (41.5) 327 (26.4) <0.001
History of diabetes (n, %) 16 (2.7) 18 (1.5) 0.091
>2 drinks alcohol/day (n, %) 120 (20.2) 278 (22.5) 0.262
Non-manual occupation (n, %) 184 (32.3) 465 (38.7) 0.009
Physical activity (inactive/occasional) (n, %) 275(46.7) 493(40.4) 0.011
Physical measurements
Body mass index (kg/m2) 25.9 (3.4) 25.4 (3.3) 0.001
Systolic blood pressure (mmHg) 151.8 (21.8) 146.7 (20.9) <0.001
Diastolic blood pressure (mmHg) 85.7 (13.8) 82.8 (13.2) <0.001
FEV1 (L/min)a 3.10 (0.65) 3.21 (0.71) 0.002
Blood sample
Total cholesterol (mmol/L) 6.64 (1.06) 6.20 (0.99) <0.001
HDL cholesterol (mmol/L) 1.09 (0.27) 1.15 (0.27) <0.001
Triglyceride (mmol/L)b 1.95 (0.69, 5.51) 1.70 (0.57, 5.02) <0.001
IL-18 (pg/mL)b 302.0 (117.1, 779.1) 275.4 (106.8, 710.6) 0.001
C-reactive protein (mg/L)b 2.51 (0.30, 20.95) 1.45 (0.14, 15.11) <0.001
IL-6 (pg/mL)b 2.75 (0.81, 9.32) 2.29 (0.65, 8.11) <0.001
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(a FEV1 adjusted for [(cohort mean height)2/height2].
b Geometric mean and 95% range.
. Results
.1. British Regional Heart Study
Established vascular risk factors showed highly signiﬁcant
ifferences between cases and controls in the expected direc-
ions (Table 1). Geometric mean IL-18 levels were higher among
ases than controls (percentage difference 9.0%, 95% CI 4.0–14.0%,
<=0.001). Baseline IL-18 levels in the control population were
trongly related to cigarette smoking, triglyceride, HDL-cholesterol
inversely), acute phase proteins (CRP, SAA), IL-6, cellular adhe-
ion molecules (ICAM-1, VCAM-1, E-selectin, P-selectin) and with
aemostatic variables (vWF, ﬁbrin D-dimer and t-PA). IL-18 lev-
ls were weakly related to diastolic BP, but were not appreciably
elated to age, BMI, total cholesterol, physical activity or to other
stablished CHD risk factors (Table 2). In a comparison of men in
he top third compared with those in the bottom third of baseline
L-18 levels, the age-adjusted OR for CHD was 1.55 (95% CI 1.21,
.98) (Table 3). Adjustment for cigarette smoking slightly atten-
ated this OR, while additional adjustment for other vascular risk
actors reduced theOR to 1.30 (95%CI 0.99, 1.69). Additional adjust-
ent for CRP and IL-6 reduced the OR to 1.12 (95% CI 0.81, 1.55).
n the last adjusted model, the OR for CVD for a doubling in CRP
as 1.23 (95% CI 1.13, 1.33) and 1.15 (95% CI 1.00, 1.33) for a dou-
ling in IL-6 (data not presented). Repeating the analysis excluding
en with established CHD had little material impact on the results
Table 3). An RDR of 0.71 (95% CI 0.61, 0.81) was calculated for the
58 men with IL-18 levels measured 4 years apart [25]. The OR of
HD among men in the top third of IL-18 compared with the low-
st third, adjusted for age and vascular risk factors, increased from
.30 (95% CI 0.99, 1.69) to 1.45 (95% CI 0.99, 2.09) after correction
or regression dilution.
.2. Meta-analysis
From 458 studies identiﬁed, eleven relevant prospective stud-
es (ﬂow diagram, Web Fig. 1), plus the BRHS were selected for the
eta-analysis. Of the twelve included, eightwere based on approx-mately general populations [11–14,26–28] and four on patients
ith CAD or at high risk of CHD [9,10,29,30]; in all, these studies
ncluded a total of 3047 CVD cases and 11,071 control individuals
Web Table 2). We were able to obtain relevant estimates for mod-els 1 and 2 for all twelve studies and for model 3 for eleven studies
(Web Table 3). In nine studies the outcome was CHD and in the
other three CHD was combined with other cardiovascular disease
(CVD) e.g. stroke, and reported here as CVD. All studies except one
[26] used ELISAs produced by one of two manufacturers. Estimates
of the age-adjusted ORs and HRs (Fig. 1) showed little evidence
of heterogeneity between studies (I2, 12%, p=0.327); there was
no strong evidence of bias (examining the funnel plot for asym-
metry and Egger test, p=0.108; Begg test, p=0.451, Web Fig. 2).
The age and gender adjusted RR of CVD (for the highest third of
IL-18 compared with the lowest third of IL-18) in a ﬁxed-effect
meta-analysis was 1.64 (95% CI 1.48, 1.83). Adjustment for estab-
lished cardiovascular risk factors reduced the RR to 1.35 (95% CI
1.25, 1.51); additional adjustment for inﬂammatory markers (CRP
and IL-6) somewhat reduced the RR to 1.34 (95% CI 1.17, 1.53),
although the increase in RR remained statistically signiﬁcant (Web
Fig. 3). In age-adjusted analyses, RR estimates in approximately
general populations (1.55 [95% CI 1.36, 1.77]) and patients with
CAD (1.82 [95% CI 1.53, 2.18]) respectively were not appreciably
different (F=2.13, p=0.176). Similarly, there was no evidence of a
systematicdifference inRRestimatesbetweenstudieswith theout-
come of CHD (1.62 [95% CI 1.43, 1.81]) compared to CVD (RR 1.79
[95% CI 1.36, 2.34]) (F=0.38, p=0.552). Further meta-regressions
did not ﬁnd consistent evidence that RR estimated differed by gen-
der, geographic location, sample storage temperature, study date
or follow-up period (data not presented). The RR for CVD among
participants in the top third of IL-18 compared with the lowest
third and adjusted for age, gender, lipids, BMI and behavioural risk
factors corrected using the RDR of 0.71 was 1.53 (95% CI 1.37, 1.79).
3. Discussion
In this large population-based prospective study among mainly
healthy middle-aged men, baseline circulating IL-18 concentra-
tions were positively associated with CHD risk. Once conventional
vascular risk factors were accounted for, the strength of the inde-
pendent relationship was modest, with CHD risk in the highest
third of the IL-18 distribution being approximately 30% higher
than that in the lowest third. Positive associations between IL-18
and CHD are consistent with its postulated role in atherosclerotic
plaque progression and rupture [6,7]. IL-18 is an important regula-
tor of both innate and acquired immune responses [5]. It is present
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Table 2
Association between IL-18 (thirds) and cardiovascular risk factors in the coronary heart disease control sample (n=1237).
Thirds of IL-18
Low 29–233pg/mL
(n=411)
Middle 234–345pg/mL
(n=413)
High 346–2068pg/mL
(n=414)
p (trend), adjusted
for age and town
Mean or n SE or % Mean or n SE or % Mean or n SE or %
Age 52.5 0.3 52.1 0.3 52.8 0.3 0.609
Current smoker (n, %) 133 32.4 188 45.7 200 48.3 <0.001
>2 drinks alcohol/day (n, %) 98 23.8 86 20.9 94 22.7 0.558
Evidence of CHD at entry (n, %) 106 25.8 113 27.4 108 26.1 0.773
History of diabetes at baseline (n, %) 7 1.7 6 1.5 6 1.5 0.770
Non-manual occupations (n, %) 181 45.1 145 36.4 139 34.3 0.016
Physical Activity (inactive/occasional) (n, %) 152 37.7 169 41.6 172 41.8 0.656
Body mass index (kg/m2) 25.1 0.2 25.5 0.2 25.6 0.2 0.052
Systolic blood pressure (mmHg) 144.6 1.0 146.9 1.0 148.4 1.0 0.033
Diastolic blood pressure (mmHg) 81.0 0.6 83.8 0.6 83.4 0.6 0.018
FEV1 [adjusted] (L/min)a 3.26 0.04 3.20 0.04 3.16 0.04 0.617
Total cholesterol (mmol/L) 6.14 0.05 6.23 0.05 6.21 0.05 0.394
HDL cholesterol (mmol/L) 1.20 0.01 1.15 0.01 1.11 0.01 <0.001
Triglycerides (mmol/L)b 0.19 0.01 0.22 0.01 0.26 0.01 <0.001
Haematocrit (%) 41.91 0.45 42.79 0.45 42.45 0.45 0.700
Homocysteine (mmol/L)b 1.10 0.01 1.12 0.01 0.16 0.01 0.011
Insulin (mU/L)b 1.07 0.02 1.05 0.02 1.13 0.02 0.032
Glucose (mmol/L)b 0.74 0.004 0.74 0.004 0.74 0.004 0.690
C-reactive protein (mg/L)b 0.05 0.03 0.15 0.03 0.30 0.03 <0.001
Serum amyloid A protein (mg/L)b 0.81 0.02 0.83 0.02 0.88 0.02 0.003
White cell count (109/L)b 0.83 0.01 0.85 0.01 0.85 0.01 0.011
Albumin (g/L) 44.7 0.1 44.6 0.1 44.3 0.1 0.003
Globulin (g/L) 28.9 0.2 28.9 0.2 29.3 0.2 0.101
E-selectin (ng/mL)b 1.74 0.01 1.77 0.01 1.82 0.01 <0.001
P-selectin (ng/mL)b 2.00 0.01 2.01 0.01 2.07 0.01 0.001
ICAM 1 (ng/mL)b 2.43 0.01 2.47 0.01 2.52 0.01 <0.001
VCAM 1 (ng/mL)b 2.62 0.01 2.64 0.01 2.66 0.01 0.008
von Willebrand factor (IU/dL)b 2.00 0.01 2.01 0.01 2.05 0.01 <0.001
Fibrin D-dimer (ng/mL)b 1.86 0.02 1.88 0.02 1.93 0.02 0.008
t-PA (ng/mL)b 0.97 0.01 1.01 0.01 1.06 0.01 <0.001
IL-6 (pg/mL)b 0.31 0.01 0.36 0.01 0.41 0.01 <0.001
i
u
t
n
m
v
o
o
T
Oa FEV adjusted for [(cohort mean height)2/height2].
b Values are transformed to log base 10.
n human atherosclerotic lesions, and at higher concentrations in
nstable plaques [6]. In animal models, IL-18 administration leads
o increases in atherosclerotic lesion size and promotes increased
umbers of T-lymphocytes in the lesion [31], suggesting that it
ay be of pathogenic importance in the tissue. We show that ele-
ated IL-18 is associated with increased CVD risk, but whether this
bservation is indicative of IL-18 being causal in plaque rupture,
r whether rupture prone plaques “leak” IL-18 into the circulation
able 3
dds ratios for coronary heart disease in men by thirds of IL-18 and for continuous (doub
IL-18 values Cases Controls OR (95% CI)
Thirds N N Model 1a
All participants, n=1833 (range pg/mL)
346–2068 242 414 1.55 (1.21, 1.9
234–345 193 413 1.24 (0.96, 1.5
29–233 160 411 1
Total 595 1238
Continuous doubling of IL-18e 1.30(1.12,1.50
p trende 0.003
Participants without baseline CHD (BRHS deﬁnition), n=1259 (range pg/mL)
346–2068 150 306 1.63 (1.19 2.2
234–345 105 300 1.16 (0.84 1.6
47–233 93 305 1
Total 348 911
Continuous doubling of IL-18e 1.31 (1.09, 1.5
p trende 0.030
a Model 1 = age+ town.
b Model 2 =Model 1 + smoking.
c Model 3 =Model 2 +blood pressure, total cholesterol, HDL, body mass index, history o
d Model 4 =Model 3 + log10 C-reactive protein (mg/L), log10 IL-6 (pg/mL).
e OR of MI per 1 log2 increase in log2(IL-18), i.e. a doubling of IL-18, p value for trend us(reverse causality), or the association is coincidental, is currently
unknown.
In addition to providing the largest prospective study of IL-18
and CHD risk reported to date (with almost twice as many CHD
cases as the next largest study), the meta-analysis results, based on
data from all published prospective studies, suggest that there is
an independent association between IL-18 and CHD risk, indepen-
dent of classical risk factors, with higher risk consistently observed
ling of) IL-18.
Model 2b Model 3c Model 4d
8) 1.48(1.15, 1.90) 1.30 (0.99, 1.69) 1.12 (0.84, 1.49)
9) 1.19 (0.92, 1.54) 1.06 (0.81, 1.39) 1.04 (0.78, 1.38)
1 1 1
) 1.23(1.09, 1.47) 1.21(1.03, 1.42) 1.14(0.96, 1.34)
0.008 0.032 0.191
2) 1.53 (1.12, 2.10) 1.29 (0.92, 1.80) 1.11 (0.77, 1.50)
0) 1.09 (0.79, 1.52) 1.03 (0.73, 1.46) 1.05 (0.73, 1.51)
1 1 1
7) 1.27 (1.06, 1.53) 1.16 (0.95, 1.41) 1.09 (0.88, 1.35)
0.056 0.343 0.758
f diabetes, CHD, social class, physical activity.
ing IL-18 as a continuous variable.
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sFig. 1. Associations of baseline IL-18 level and risk of onset of CHD in 1
n all studies. The effect is maintained even after adjustment for
oth established cardiovascular risk markers and for inﬂammatory
arkers. In the BRHS data the association of IL-18 with incident
HDwas not signiﬁcant after adjustment for CRP and IL-6, although
RP remained an independent predictor of CHD suggesting sepa-
ate pathways from CRP and IL-18 to CHD risk. The RR adjusted for
ther inﬂammatory markers was of the order of 35% in the meta-
nalysis, so the strength of association with CHD is slightly smaller
han that estimated forCRP ina recentmeta-analysis, similar to that
or erythrocyte sedimentation rate and stronger than that for von
illebrand factor [3]. However it is possible that intra-individual
ariability of IL-18 could lead to under-estimation of the strength of
ts associationwith CHD risk, as previously reported for IL-6 [4].We
eport, for the ﬁrst time, a serial study of IL-18 measurements over
years, and use this data to correct for regression dilution bias.
he RDR-corrected RR adjusted for established risk factors from
he meta-analysis strengthened somewhat from 1.35 to 1.53 (95%
I 1.37, 1.79); more similar to the magnitude of the uncorrected
djusted association of CRP with CHD [3].
However, in the present study population, after adjustment for
stablished risk factors the strength of the association between IL-
8 and CHD was weaker than both the associations with other
stablished risk factors such as blood pressure and cholesterol
32], and the associations of other inﬂammatory markers [4,15].
hese results therefore provide little support for the value of IL-18
s a predictor of risk in individual subjects. In the north Glas-
ow MONICA cohort study (included in the meta-analysis), IL-18
dded less than 0.1% to the prediction of CVD using the ASSIGN
isk score, once standard CVD risk factors and social class were
ccounted for. They also reported that CRP, a marker consistently
ssociated with CVD events, did add to the prediction of CVD risk,
lthough other studies have found moderate or little evidence for
dditional value of inﬂammatory markers as predictors of indi-
idual risk [27]. Nevertheless, IL-18 is still of potential interest
s a causal factor in CHD, and potentially as a therapeutic tar-
et. In addition to testing of causality by Mendelian randomization
tudies [29], any trials of potential IL-18 antagonists would be ofies, adjusted for age and gender. Models ordered by statistical weight.
interest although we know of no such drugs currently in clinical
trials.
Variation within the IL18 gene has been shown to inﬂuence cir-
culating levels of IL-18 in both association studies [13,33,34], and
in a genome wide association study [35]. These SNPs have been
reported to be associated with clinical outcome in subjects with
coronary artery disease [29,36,37] but this is not seen in all stud-
ies [38,39]. IL18 SNPs also are associated with differences in IL-18
production capability by monocytes [40–42]. While single SNPs in
the gene are associated with modest effect on plasma levels, sev-
eral groups have demonstrated that certain haplotypes deﬁned by
up to ﬁve SNPs in combination are strongly associated with lower
levels of serum IL-18 in healthy individualswhere for example sub-
jects carrying two copies of the haplotype had IL-18 concentrations
15–20% lower than those carryingno copies [13,33], andwith lower
levels of serum IL-18 in individuals with cardiovascular disease,
and with protection from future cardiovascular events [29]. No
non-synonymous variation has been identiﬁed in IL18 despite exon
sequencing in a number of individuals. It is therefore likely that the
functional polymorphism(s) responsible for these observed asso-
ciations cause differences in promoter activity, mRNA splicing or
mRNA stability, but the precise mechanism is currently unknown.
It would therefore be possible to use IL18 genotypes to distin-
guish association and causation using a Mendelian randomization
approach, as has previously been done for CRP [43] and ﬁbrinogen
[44], suggesting that these factors are not causally related to CHD.
Future studies could also examine whether effect modiﬁers of any
associationsbetween IL-18andCHD;previous studieshavedemon-
strated interactions between IL-18 or IL-18 genotypes and factors
related to CHD risk (e.g. metabolic syndrome [30], hypertension
[45] or cigarette smoking [46]), any such interactions could change
the predictive value of circulating IL-18 levels.
Compared with previous reports on IL-18, the present
community-based study has considerably more CHD events and
includes measurements of a wide range of potential confounding
factors at study entry. For the ﬁrst time, we report a meta-analysis
of published studies and the potential impact of regression dilution
2 roscle
b
g
v
m
i
e
a
C
m
f
e
o
p
p
o
t
f
n
a
a
o
d
a
b
w
4
t
r
C
A
v
f
D
K
J
T
P
T
f
w
G
B
R
a
A
t
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[32 B.J.M.H. Jefferis et al. / Athe
ias. This study, like most others, is limited by having only a sin-
le measure of IL-18. However we estimated the intra-individual
ariability in serum IL-18 levels in a separate sub-study of men
easured four years apart. Estimates suggested that the stabil-
ty of serum IL-18 is similar to several established risk factors
.g. total cholesterol [25] and correction for within-person vari-
bility, somewhat strengthened the estimated associations with
HD or CVD. Despite prolonged sample storage before measure-
ents (approximately 24 years at −20 ◦C, which was suboptimal
or such a long time span), which might have resulted in under-
stimation of the association of IL-18 with CHD, the validity of
ur IL-18 levels is supported by their consistency with those in
reviously reported studies [11,12], by their associationswith inde-
endently assessed inﬂammatory markers and by the consistency
f the ﬁndings with those of the previously published prospec-
ive studies. Themeta-analysis of prospective studies included data
romall studies identiﬁed from threemajor databases andprovided
o strong evidence for small study bias. Additionally, sensitivity
nalyses excluding studies with CVD rather than CHD endpoints
nd based in high risk rather than general populations did not alter
ur conclusions. While the analysis of British Regional Heart Study
ata included only men, nine of the twelve studies in the meta-
nalysis includedwomen, soour conclusions about the associations
etween IL-18 and CVD events are generalised to both men and
omen.
. Conclusions
The results of the present study and the meta-analysis suggest
hat IL-18 is prospectively and independently associated with CHD
isk, but the association is modest in strength.
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